KBC Group
RYTM icon

KBC Group’s Rhythm Pharmaceuticals RYTM Stock Holding History

KBC Group’s Portfolio RYTM Stock Details RYTM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q3 		$163K Hold
1,707
– – ﹤0.01% 1112
2026
Q2 		$190K Hold
1,707
– – ﹤0.01% 1067
2026
Q1 		$148K Hold
1,707
– – ﹤0.01% 1100
2025
Q4 		$183K Hold
1,707
– – ﹤0.01% 948
2025
Q3 		$172K Hold
1,707
– – ﹤0.01% 967
2025
Q2 		$108K Sell
1,707
-544
-24% -$33.3K ﹤0.01% 1155
2025
Q1 		$119K Hold
2,251
– – ﹤0.01% 1382
2024
Q4 		$126K Buy
2,251
+988
+78% +$54.6K ﹤0.01% 1396
2024
Q3 		$66K Hold
1,263
– – ﹤0.01% 1566
2024
Q2 		$52K Hold
1,263
– – ﹤0.01% 1590
2024
Q1 		$55K Hold
1,263
– – ﹤0.01% 1499
2023
Q4 		$58K Buy
1,263
+452
+56% +$14.3K ﹤0.01% 1415
2023
Q3 		$19K Buy
+811
New +$18.2K ﹤0.01% 1887

Other funds holding RYTM

BlackRock
BlackRock New York $6.79T AUM 37.06% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.84T AUM 33.86% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.21T AUM
Primecap Management
Primecap Management Pasadena, California $161B AUM 86.05% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.76T AUM
State Street
State Street Boston, Massachusetts $3.44T AUM 36.12% 1-Year Est. Return
Westfield Capital Management
Westfield Capital Management Boston, Massachusetts $30.6B AUM 42.55% 1-Year Est. Return
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $71.4B AUM 33.43% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $704B AUM 26.74% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.92T AUM 36.1% 1-Year Est. Return

KBC Group's RYTM Position: Q3 2026 in Review

KBC Group held its Rhythm Pharmaceuticals (RYTM) position steady in Q3 2026 at 1,707 shares worth $163K. The position accounts for ﹤0.01% of the portfolio, ranked #1112.

KBC Group first reported a position in RYTM in Q3 2023 and has held it in 13 quarters since. The position peaked at $190K in Q2 2026. 239 funds tracked by Wall St. Rank hold RYTM as of Q3 2026.

  • KBC Group held 1,707 shares of Rhythm Pharmaceuticals worth $163K as of Q3 2026.
  • KBC Group left its Rhythm Pharmaceuticals share count unchanged in Q3 2026.
  • Rhythm Pharmaceuticals made up ﹤0.01% of KBC Group's portfolio in Q3 2026, its #1112 holding.
  • KBC Group first reported a position in Rhythm Pharmaceuticals in Q3 2023 and has held it in 13 quarters since.
  • KBC Group's Rhythm Pharmaceuticals position peaked at $190K in Q2 2026.
  • 239 funds tracked by Wall St. Rank held Rhythm Pharmaceuticals as of Q3 2026.

Based on KBC Group's 13F filing for Q3 2026, filed 22 Oct 2026.